LOGIN  |  REGISTER
Viking Therapeutics
Chimerix

MaxCyte to Participate in Upcoming Investor Conferences

June 01, 2023 | Last Trade: US$3.88 0.02 0.52

ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate at the following investor conferences:

  • William Blair 43rd Annual Growth Stock Conference
    Thursday, June 8 at 8:00 a.m. Central Time
  • TD Cowen 2nd Annual Tools/Dx Revolution
    Monday, June 26th at 3:10 PM Pacific Time

A live and archived webcast of the William Blair Presentation will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.

MaxCyte Contacts:

US IR Adviser 
Gilmartin Group 
David Deuchler, CFA 
+1 415-937-5400 
This email address is being protected from spambots. You need JavaScript enabled to view it.  

US Media Relations 
Spectrum Seismic Collaborative 
Valerie Enes 
+1 408-497-8568 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Nominated Adviser and Joint Corporate Broker 
Panmure Gordon 
Emma Earl / Freddy Crossley 
Corporate Broking 
Rupert Dearden 
+44 (0)20 7886 2500 

UK IR Adviser 
Consilium Strategic Communications 
Mary-Jane Elliott 
Chris Welsh 
+44 (0)203 709 5700 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB